- Home
- QIPT vs VERU Comparison
QIPT vs VERU Comparison
Compare QIPT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- VERU
- Stock Information
- Founded
- QIPT 1993
- VERU 1971
- Country
- QIPT United States
- VERU United States
- Employees
- QIPT N/A
- VERU N/A
- Industry
- QIPT
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- VERU Health Care
- Exchange
- QIPT Nasdaq
- VERU Nasdaq
- Market Cap
- QIPT 103.8M
- VERU 107.2M
- IPO Year
- QIPT N/A
- VERU 1990
- Fundamental
- Price
- QIPT $2.48
- VERU $0.65
- Analyst Decision
- QIPT Strong Buy
- VERU Strong Buy
- Analyst Count
- QIPT 3
- VERU 4
- Target Price
- QIPT $7.67
- VERU $4.00
- AVG Volume (30 Days)
- QIPT 203.1K
- VERU 1.1M
- Earning Date
- QIPT 12-16-2024
- VERU 02-06-2025
- Dividend Yield
- QIPT N/A
- VERU N/A
- EPS Growth
- QIPT N/A
- VERU N/A
- EPS
- QIPT N/A
- VERU N/A
- Revenue
- QIPT $245,915,000.00
- VERU $16,886,419.00
- Revenue This Year
- QIPT $11.15
- VERU N/A
- Revenue Next Year
- QIPT $4.68
- VERU N/A
- P/E Ratio
- QIPT N/A
- VERU N/A
- Revenue Growth
- QIPT 16.17
- VERU 3.62
- 52 Week Low
- QIPT $2.30
- VERU $0.36
- 52 Week High
- QIPT $5.29
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- QIPT 40.48
- VERU 42.01
- Support Level
- QIPT $2.30
- VERU $0.60
- Resistance Level
- QIPT $3.16
- VERU $0.82
- Average True Range (ATR)
- QIPT 0.16
- VERU 0.07
- MACD
- QIPT -0.04
- VERU -0.01
- Stochastic Oscillator
- QIPT 14.14
- VERU 22.32
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.